SETH D. BILAZARIAN, M.D.

DANVERS, MA

Research Active
Internal Medicine - Cardiovascular Disease NPI registered 21+ years 8 publications 1997 – 2025 NPI: 1427050640
Heart-Assist DevicesEquipment DesignExtracorporeal Membrane OxygenationAngiographyHemodynamicsHeart VentriclesBlood Flow VelocityCardiologyShock, CardiogenicFemoral ArteryRegional Blood FlowBicarbonatesHeart Defects, CongenitalCardiologistsVascular Access Devices

Practice Location

22 CHERRY HILL DR
DANVERS, MA 01923-2575

Phone: (978) 646-1810

What does SETH BILAZARIAN research?

Dr. Bilazarian studies various aspects of heart health, particularly looking at how certain medical devices can improve blood flow in patients undergoing treatments for heart conditions. He investigates the prevalence of metabolic syndrome, a serious cluster of health issues linked to heart disease, especially among younger patients experiencing heart attacks. Additionally, he assesses heart abnormalities in specific patient populations, helping clinicians understand risks and predict outcomes more accurately.

Key findings

  • In a study on reperfusion sheaths, Dr. Bilazarian found that blood flow rates improved from 167 ml/min to 356 ml/min when using an active pressure system, demonstrating that device configuration is crucial for enhancing blood flow.
  • In his 2007 research, he revealed that 72% of young heart attack patients undergoing percutaneous coronary intervention had metabolic syndrome, indicating a significant risk factor for future cardiovascular issues.
  • His study on AL amyloidosis showed that 31% of patients with heart involvement had late electrical signals on tests, compared to 9% of those without heart issues, highlighting the need for closer monitoring of these patients.

Frequently asked questions

Does Dr. Bilazarian study heart conditions?
Yes, he extensively researches various heart conditions and treatments, focusing on improving patient outcomes.
What treatments has Dr. Bilazarian researched?
He has studied the effectiveness of mechanical circulatory support devices and procedures like percutaneous coronary intervention.
Is Dr. Bilazarian's work relevant to young heart attack patients?
Absolutely, his studies reveal significant risk factors like metabolic syndrome that directly impact young patients' heart health.

Publications in plain English

Flow characteristics of reperfusion sheaths when utilizing large bore mechanical circulatory support devices.

2025

Cardiovascular revascularization medicine : including molecular interventions

Aziz IN, Jabri A, Xu Y, Bilazarian S, Bentley D +8 more

Plain English
This research looked at how well different medical devices called reperfusion sheaths allow blood to flow when used with large bore support devices. They found that changing the size of these sheaths had little effect on flow rates, with minimal increases observed even with larger sizes—flow rates ranged from 167 ml/min to 179 ml/min as sheath size increased. Importantly, using a specific setup with an active pressure system dramatically increased flow to 356 ml/min, demonstrating that certain configurations can significantly improve blood flow and potentially reduce complications for patients. Who this helps: This benefits patients undergoing procedures involving mechanical circulatory support, particularly those at risk for limb circulation issues.

PubMed

Comment: Analysis of Bicarbonate-Based Purge Solution in Patients With Cardiogenic Shock Supported Via Impella Ventricular Device.

2023

The Annals of pharmacotherapy

Moretz JD, Corbett S, Bilazarian S

PubMed

Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank.

2021

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Naidu SS, Baron SJ, Eng MH, Sathanandam SK, Zidar DA +81 more

Plain English
The 2021 Think Tank organized by the Society for Cardiovascular Angiography and Interventions (SCAI) gathered experts in interventional cardiology to discuss important topics across four key areas: treating blocked arteries, endovascular procedures, heart structure issues, and congenital heart defects. The goal of these discussions was to generate ideas and action steps to improve practices in these areas. This matters because advancements in interventional cardiology can lead to better patient outcomes and more effective treatments. Who this helps: Patients with heart conditions and the doctors treating them.

PubMed

Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.

2020

American heart journal

Samsky M, Krucoff M, Althouse AD, Abraham WT, Adamson P +23 more

PubMed

Letter by Bilazarian et al. regarding the article, "Adverse events and modes of failure related to Impella RP: Insights from the Manufacturer and User Facility Device Experience (MAUDE) database" by Khalid et al.

2019

Cardiovascular revascularization medicine : including molecular interventions

Bilazarian S, Bolt W

PubMed

A case of lipid core plaque progression and rupture at the edge of a coronary stent: elucidating the mechanisms of drug-eluting stent failure.

2010

Circulation. Cardiovascular interventions

Waxman S, Freilich MI, Suter MJ, Shishkov M, Bilazarian S +3 more

PubMed

Prevalence of metabolic syndrome in patients < or =45 years of age with acute myocardial infarction having percutaneous coronary intervention.

2007

The American journal of cardiology

Chung EH, Curran PJ, Sivasankaran S, Chauhan MS, Gossman DE +7 more

Plain English
This study looked at young patients aged 18 to 45 who had heart attacks and were treated with a procedure called percutaneous coronary intervention. Out of 223 patients, 161 (about 72%) were found to have metabolic syndrome, which is a group of health risks linked to heart disease. This is important because it highlights that many young heart attack patients have metabolic syndrome, putting them at greater risk for future health problems. Who this helps: This information benefits doctors and healthcare providers treating young patients with heart issues.

PubMed

Signal-averaged electrocardiography in patients with AL (primary) amyloidosis.

1997

American heart journal

Dubrey SW, Bilazarian S, LaValley M, Reisinger J, Skinner M +1 more

Plain English
This study examined 133 patients with AL amyloidosis to understand the relationship between heart abnormalities and death risk. Researchers found that 31% of patients with signs of heart involvement from imaging tests had late electrical signals, compared to only 9% of those without heart issues. Out of the group, 106 patients died during the follow-up, highlighting that both abnormal heart tests and late potentials can predict the risk of heart-related deaths. Who this helps: This information is valuable for doctors treating AL amyloidosis patients, as it helps them identify those at higher risk for sudden cardiac death.

PubMed

Frequent Co-Authors

Herbert D Aronow Alexander G Truesdell Timothy D Henry George D Dangas Imran Naeem Aziz Ahmad Jabri Ying Xu Dana Bentley Amir Kaki Allison Dupont

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.